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Abstract
Background: High early mortality in patients with HIV-1 starting antiretroviral therapy (ART) in sub-Saharan Africa,
compared to Europe and North America, is well documented. Longer-term comparisons between settings have been
limited by poor ascertainment of mortality in high burden African settings. This study aimed to compare mortality up to
four years on ART between South Africa, Europe, and North America.
Methods and Findings: Data from four South African cohorts in which patients lost to follow-up (LTF) could be linked to the
national population register to determine vital status were combined with data from Europe and North America. Cumulative
mortality, crude and adjusted (for characteristics at ART initiation) mortality rate ratios (relative to South Africa), and
predicted mortality rates were described by region at 0–3, 3–6, 6–12, 12–24, and 24–48 months on ART for the period 2001–
2010. Of the adults included (30,467 [South Africa], 29,727 [Europe], and 7,160 [North America]), 20,306 (67%), 9,961 (34%),
and 824 (12%) were women. Patients began treatment with markedly more advanced disease in South Africa (median CD4
count 102, 213, and 172 cells/ml in South Africa, Europe, and North America, respectively). High early mortality after starting
ART in South Africa occurred mainly in patients starting ART with CD4 count ,50 cells/ml. Cumulative mortality at 4 years
was 16.6%, 4.7%, and 15.3% in South Africa, Europe, and North America, respectively. Mortality was initially much lower in
Europe and North America than South Africa, but the differences were reduced or reversed (North America) at longer
durations on ART (adjusted rate ratios 0.46, 95% CI 0.37–0.58, and 1.62, 95% CI 1.27–2.05 between 24 and 48 months on ART
comparing Europe and North America to South Africa). While bias due to under-ascertainment of mortality was minimised
through death registry linkage, residual bias could still be present due to differing approaches to and frequency of linkage.
Conclusions: After accounting for under-ascertainment of mortality, with increasing duration on ART, the mortality rate on
HIV treatment in South Africa declines to levels comparable to or below those described in participating North American
cohorts, while substantially narrowing the differential with the European cohorts.
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Introduction
Antiretroviral therapy (ART) for HIV-infected patients has been
routinely available in some Sub-Saharan African settings for more
than a decade. Early analyses of treatment cohorts in this region
focussed on demonstrating the feasibility and subsequently the
scalability of ART provision in high-burden but resource-
constrained settings [1–5]. In South Africa alone more than 2
million people have been initiated on ART, and there is emerging
evidence of substantial population-level declines in mortality [6].
Most data on long-term prognosis of patients started on ART
continue to be derived from Europe and North America [7], in
part because of concerns about mortality ascertainment in high
burden settings [8]. Published comparisons between settings, and
prognostic models from resource-limited settings, are limited to the
first one or two years on ART [9–11]. Measured early mortality
on ART has been higher in resource-limited settings including
Southern Africa [9], with explanations for these differences
focussing on demographic, socio-economic, biological, and health
service factors [12]. Even in well-resourced settings there is
substantial heterogeneity in mortality by region, individual
cohorts, and according to patient characteristics [13,14].
The availability in South Africa of an effective national vital
registration system through a national population register (NPR)
provides an opportunity to correct for under-ascertainment of
mortality and to compare mortality between South Africa and other
settings [15]. The aim of this analysis was to compare mortality up
to four years on ART between cohorts from South Africa that were
linked to the death registry, and cohorts from Europe and North
America with near-complete ascertainment of deaths.
Methods
Ethics Statement
At all sites, institutional review boards (IRBs) had approved the
collection of data and submission to the data centres at the
Universities of Cape Town (IeDEA-SA) and Bristol (ART-CC).
The IRBs at the universities of Cape Town and Bristol
additionally provided respective approval for the IeDEA-SA and
ART-CC collaboration activities under which this project was
conducted. Both datasets were assembled in 2010.
Settings and Cohorts
The South African cohorts form part of the International
Epidemiologic Databases to Evaluate AIDS Southern African
(IeDEA-SA) collaboration [16]. Data were restricted to the four
cohorts, out of eight cohorts in South Africa, that were able to link
to the NPR (Table S1). These cohorts include government
primary-care clinics in Cape Town, hospital clinics in Johannes-
burg and Durban, and a rural program in KwaZulu-Natal
Province. The ART Cohort Collaboration (ART-CC) brings
together cohorts of treatment-naı¨ve adult patients from Europe
and North America [17]. Data were included from six North
American and nine European cohorts (see collaborating centres).
Patient Eligibility and Treatment Protocols
Eligible patients with HIV-1 were not previously exposed to
ART and started ART between 2001 and 2009 aged 16 years and
over. In South Africa adults were eligible for treatment if they had
a CD4 count ,200 cells/ml, or a WHO stage IV illness other than
extra-pulmonary tuberculosis. Initial regimens included a nucle-
oside reverse-transcriptase inhibitor (NRTI) backbone of lamivu-
dine with either zidovudine or stavudine (default from 2004),
combined with a non-nuceloside reverse-transcriptase inhibitor
(NNRTI), either nevirapine or efavirenz. Monitoring comprised
six-monthly viral load and CD4 count testing. The cohorts in
Europe and North America followed country-specific treatment
guidelines, which generally comprised a first-line regimen of two
NRTIs and either an NNRTI or boosted protease inhibitors. A
wider range of NRTIs were accessible than in South Africa,
including tenofovir and abacavir [18]. Monitoring of virologic and
immunologic response was quarterly.
Loss to Follow-up and Mortality Ascertainment
Loss to follow-up (LTF) was determined by closing the analysis
for each cohort six months before database closure, and defining
patients with no recorded death or visit in the window between
analysis and database closure as being lost at their last visit.
Patients with no outcome before analysis closure were censored at
analysis closure.
The primary outcome was death from all causes. For each of the
South African cohorts, civil identification numbers, where
available, were crosschecked with the NPR prior to data transfer
to confirm or ascertain dates of death. The European and North
American cohorts recently described the frequency of death
registry linkage as well as their own assessments of the
completeness of mortality ascertainment [13]. All of the North
American cohorts link to a population-based death registry at least
annually, while only three of the European cohorts reported
regular searching of a registry for unrecorded deaths (one cohort
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annually for patients ,65 years old, and one each every two and
three years, respectively). Estimates of completeness of mortality
ascertainment ranged from 75% to 98%.
NPR data in South Africa were only able to distinguish natural from
non-natural causes of death. Causes of death from most of the
European and North American cohorts were coded using a procedure
adapted from the CoDe protocol, [19,20] and grouped as natural or
non-natural, AIDS or non-AIDS, and infection-related or other.
Statistical Methods
Patient characteristics at ART initiation (categorized or as
medians with interquartile ranges) were described by region,
including gender, age, CD4 count (within 6 months prior to
initiation), viral load, mode of transmission (men who have sex
with men, injection drug use, heterosexual, blood, other, or
unknown), and year of ART initiation (Table 1). Although HIV in
South Africa is predominantly heterosexually acquired [21,22],
data on mode of transmission were not available at an individual
patient level for the South African patients. Clinical stage was
characterised as advanced if WHO stage III or IV (South Africa)
or CDC stage C (Europe and North America). Missing baseline
values were multiply imputed by a chained equations approach
and all resulting estimations were combined across five imputed
datasets using Rubin’s rules [23,24]. The imputation model
included baseline gender, CD4 count, viral load, year of ART
initiation, HIV clinical stage, cohort, and region as well as the
outcomes of duration of follow-up (continuous time) and mortality
(see Textbox S1). The absence of data on hepatitis C (HCV) in
South Africa precluded its inclusion in any combined analyses.
Among patients LTF in South Africa, those with civil
identification numbers and therefore linkable to the NPR were
up-weighted to represent all patients lost: within each cohort we
took the inverse of the modelled probability (based on age, gender,
CD4 count, year of ART initiation, and duration on ART when
lost) of having a civil identifier as the weight for each linkable
patient, in order to account for any differences between linkable
and other patients LTF (Table S2). Patients not LTF received a
weight of one, while those LTF and not linkable were given a
weight of zero [25]. The weighted data for South Africa were
combined with the data from Europe and North America for the
Kaplan-Meier estimates and exponential models described below.
Cumulative mortality up to four years on ART by region was
estimated using a weighted Kaplan-Meier approach with boot-
strapped (200) confidence intervals, for all patients and separately
for patients with initial CD4 counts ,50 and 50–199 cells/ml [25].
Mortality rates were described by region and individual cohort at
0–3, 3–6, 6–12, 12–24, and 24–48 months on ART. Shorter
intervals were selected in the first year on ART due to the sharply
declining mortality hazard soon after starting ART, and rapidly
changing relative mortality comparing Europe and North America
to South Africa. In addition to crude rates, to demonstrate inter-
regional and inter-cohort heterogeneity in rates after adjustment,
mortality rates were predicted within each time period after
starting ART from an adjusted piecewise exponential parametric
survival model for women aged 30–45 starting ART with a CD4
count 100–199 cells/ml, advanced clinical stage, viral load 4–5
log10 copies/ml, and starting ART in 2004–2007. The use of the
exponential model simplified the prediction of rates for each
duration interval on ART, while the implicit assumption of
constant hazards within each interval produced almost identical
inter-regional comparative mortality estimates when compared to
piecewise spline-based flexible parametric models. Crude and
similarly adjusted (for baseline gender, CD4 count, clinical stage,
viral load, and calendar period) rate ratios were estimated at each
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duration for Europe and North America compared to South
Africa (Table 2). Full outputs from these models together with the
numbers of patients included and number of deaths are provided
in Table 3. We performed several sensitivity analyses: restricted to
particular patients (mode of HIV acquisition, calendar period of
enrolment) or cohorts (self-reported mortality ascertainment level
or frequency of registry linkage); upweighting the predicted
regional mortality rates by the inverse of the weighted estimate
of ascertainment completeness [13]; randomly allocating 20% of
patients LTF in both Europe and North America to have died on
Table 2. Mortality rate ratios comparing Europe and North America to South Africa by duration on antiretroviral therapy,
adjustment for baseline patient characteristics, and restricted to specific patients and cohorts in sensitivity analyses.
Mortality Rate Ratio Duration on ART (Months)
0–3 3–6 6–12 12–24 24–48
Crude mortality rate ratio compared to South Africa (and 95% CI)
Europe 0.16 (0.14–0.19) 0.22 (0.18–0.26) 0.26 (0.22–0.31) 0.33 (0.28–0.38) 0.48 (0.40–0.57)
North America 0.29 (0.24–0.36) 0.50 (0.39–0.63) 0.76 (0.62–0.93) 1.10 (0.92–1.31) 2.21 (1.84–2.66)
Adjusted for baseline patient characteristicsa
Europe 0.30 (0.25–0.36) 0.41 (0.31–0.54) 0.39 (0.32–0.48) 0.37 (0.30–0.47) 0.46 (0.37–0.58)
North America 0.40 (0.31–0.50) 0.72 (0.53–0.97) 0.84 (0.66–1.07) 0.94 (0.74–1.20) 1.62 (1.27–2.05)
Adjusted and corrected for cohort-reported under-ascertainment of mortalityb
Europe 0.33 (0.22–0.49) 0.45 (0.28–0.74) 0.46 (0.30–0.70) 0.42 (0.27–0.66) 0.50 (0.32–0.77)
North America 0.39 (0.26–0.58) 0.71 (0.45–1.13) 0.81 (0.54–1.21) 0.99 (0.65–1.50) 1.54 (1.02–2.30)
Adjusted and restricted to patients with sexual transmission in Europe and North America
Europe 0.28 (0.22–0.35) 0.37 (0.27–0.51) 0.37 (0.29–0.47) 0.33 (0.25–0.43) 0.46 (0.35–0.61)
North America 0.18 (0.10–0.35) 0.48 (0.25–0.89) 0.63 (0.39–1.02) 0.59 (0.37–0.93) 0.80 (0.50–1.28)
Adjusted and restricted to cohorts with mortality ascertainment reported as .90%c
Europe 0.30 (0.23–0.39) 0.42 (0.30–0.60) 0.48 (0.37–0.64) 0.38 (0.29–0.51) 0.40 (0.29–0.54)
North America 0.41 (0.32–0.53) 0.72 (0.51–1.00) 0.95 (0.73–1.24) 0.88 (0.68–1.15) 1.56 (1.19–2.04)
Adjusted and restricted to cohorts with regular death registry linkaged
Europe 0.36 (0.25–0.52) 0.39 (0.22–0.69) 0.27 (0.15–0.48) 0.49 (0.33–0.75) 0.66 (0.46–0.96)
North America 0.39 (0.30–0.50) 0.68 (0.50–0.92) 0.97 (0.73–1.28) 0.96 (0.74–1.26) 1.55 (1.18–2.04)
Adjusted after assuming 20% of patients LTF subsequently died in Europe and North America
Europe 0.41 (0.35–0.48) 0.73 (0.59–0.90) 0.87 (0.73–1.04) 1.19 (1.00–1.40) 2.34 (1.96–2.80)
North America 0.48 (0.39–0.60) 0.96 (0.74–1.24) 1.25 (1.01–1.56) 1.72 (1.41–2.10) 3.59 (2.93–4.41)
Adjusted after assuming 20% and 5% of patients LTF subsequently died in Europe and North America, respectively
Europe 0.39 (0.33–0.46) 0.74 (0.60–0.92) 0.86 (0.72–1.03) 1.22 (1.03–1.45) 2.55 (2.13–3.05)
North America 0.42 (0.33–0.52) 0.83 (0.64–1.09) 0.97 (0.76–1.23) 1.43 (1.16–1.77) 3.06 (2.49–3.78)
Adjusted and restricted to patients with heterosexual transmission in Europe and North America
Europe 0.24 (0.18–0.31) 0.37 (0.26–0.53) 0.36 (0.27–0.48) 0.34 (0.24–0.47) 0.53 (0.39–0.71)
North America 0.13 (0.04–0.40) 0.84 (0.41–1.71) 0.84 (0.44–1.62) 0.54 (0.25–1.16) 1.21 (0.66–2.21)
Adjusted and restricted to patients starting ART post-2004
Europe 0.24 (0.18–0.31) 0.41 (0.28–0.61) 0.38 (0.28–0.52) 0.30 (0.22–0.42) 0.43 (0.28–0.65)
North America 0.40 (0.28–0.56) 0.58 (0.36–0.92) 0.82 (0.57–1.18) 0.85 (0.59–1.21) 0.83 (0.47–1.44)
Adjusted and restricted to patients starting ART post-2004 and in Europe and North America, heterosexual transmission
Europe 0.20 (0.14–0.28) 0.33 (0.20–0.55) 0.32 (0.21–0.50) 0.33 (0.22–0.51) 0.37 (0.22–0.63)
North America 0.09 (0.01–0.63) 0.22 (0.03–1.55) 0.60 (0.19–1.89) 0.19 (0.03–1.34) 1.69 (0.51–5.61)
Adjusted and restricted to patients who achieved a viral load ,400 copies/ml at 6 mo on ART
Europe 0.44 (0.32–0.59) 0.39 (0.29–0.53) 0.51 (0.36–0.71)
North America 0.74 (0.49–1.11) 0.82 (0.59–1.14) 1.38 (0.96–1.98)
aAdjustments were for baseline gender, CD4 count, clinical stage, viral load, and calendar period and are detailed in Table 3.
bMortality rates were predicted from a multivariable model for each region and ART duration for a common group of patients (women aged 30–45 starting ART with a
CD4 count 100–199 cells/ml, advanced clinical stage, viral load 4–5 log10 copies/ml, and starting ART in 2004–2007), and then corrected by the inverse of the weighted
self-assessed completeness of mortality ascertainment for each region.
cBased on cohort-assessed completeness of mortality ascertainment and including seven European and six North American cohorts.
dAll North American cohorts reported linking to death registries at least annually, whereas only three European cohorts provided linkage—one annually in patients,65
years old, one every two years, and one every three years.
doi:10.1371/journal.pmed.1001718.t002
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the basis of a previous European study [26]; and differentially
allocating 20% of patients LTF in Europe and 5% in North
America to have died because of more complete checking of
mortality registries in North America being likely to result in lower
mortality in those remaining LTF.
We determined the proportion of patients in each region who
achieved virologic suppression at 6 months on ART (measured
between 3 and 9 months). We conducted a sensitivity analysis in
which mortality comparisons beyond 6 months on ART were
restricted to patients who achieved virologic suppression at 6 months.
Background mortality was compared between regions using
1990 country mortality data proportional to cohort size [27],
standardised by age and gender to the combined study population.
Results
The final analysis included 67,354 patients, with 30,467 (45%),
29,727 (44%), and 7,160 (11%) patients from South Africa,
Europe, and North America, respectively (Table 1), followed for a
median of 1.6, 3.5, and 3.2 years prior to censoring at four years.
Patients differed markedly between regions with respect to gender
and mode of transmission. In South Africa 20,306 (67%) patients
were women compared to 824 (12%) in North America.
Acquisition of HIV was attributed to heterosexual contact in
15,045 (51%) patients in Europe and 672 (9%) in North America;
data on mode of sexual transmission were not available for South
African patients. Patients were younger in South Africa compared
Table 3. Full multivariable models used to calculate mortality rate ratios comparing Europe and North America to South Africa by
duration on antiretroviral therapy.
Variables Duration on ART (Months)
0–3 3–6 6–12 12–24 24–48
Patients included (deathsa)
South Africa 30,467 (1431) 26,243 (609) 23,130 (585) 18,353 (513) 10,102 (251)
Europe 29,727 (237) 28,609 (146) 27,671 (184) 24,841 (235) 19,921 (268)
North America 7,160 (104) 6,863 (80) 6,655 (128) 5,928 (187) 4,506 (280)
Gender
Female 0.80 (0.71–0.89) 0.86 (0.72–1.02) 0.83 (0.70–0.97) 0.74 (0.63–0.88) 0.79 (0.65–0.96)
Age at ART initiation
,30 years 0.91 (0.80–1.05) 0.88 (0.72–1.09) 0.81 (0.65–1.00) 0.69 (0.55–0.86) 0.63 (0.49–0.82)
30–45 years 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
45–60 years 1.20 (1.05–1.38) 1.35 (1.11–1.63) 1.52 (1.28–1.80) 1.56 (1.32–1.84) 1.48 (1.25–1.74)
.60 years 2.39 (1.87–3.06) 2.31 (1.58–3.39) 2.00 (1.43–2.80) 2.77 (2.11–3.62) 2.55 (1.95–3.33)
Year of ART initiation
2001–2003 1.00 (0.83–1.19) 0.96 (0.77–1.20) 1.06 (0.88–1.29) 1.08 (0.92–1.28) 1.31 (1.11–1.53)
2004–2006 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
2007–2009 1.23 (1.10–1.38) 1.33 (1.12–1.58) 0.99 (0.82–1.20) 0.89 (0.72–1.11) 0.53 (0.31–0.93)
Baseline CD4 count (cells/ml)
0–24 3.40 (2.90–3.98) 3.05 (2.42–3.83) 2.40 (1.94–2.98) 1.67 (1.34–2.08) 1.26 (1.00–1.59)
25–49 2.55 (2.14–3.03) 2.07 (1.58–2.71) 1.82 (1.42–2.31) 1.38 (1.07–1.77) 1.15 (0.88–1.52)
50–99 1.51 (1.28–1.79) 1.63 (1.26–2.11) 1.52 (1.21–1.91) 1.19 (0.95–1.48) 1.17 (0.93–1.48)
100–199 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
200–349 0.77 (0.59–1.00) 0.95 (0.70–1.29) 0.88 (0.66–1.18) 0.78 (0.60–1.02) 0.71 (0.56–0.89)
350–500 0.40 (0.22–0.73) 0.52 (0.27–1.01) 0.49 (0.27–0.88) 0.43 (0.27–0.68) 0.75 (0.54–1.05)
Baseline viral load (log10 copies/ml)
,4 0.98 (0.79–1.21) 1.11 (0.78–1.59) 1.02 (0.79–1.32) 1.08 (0.87–1.34) 1.03 (0.78–1.38)
4–5 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
.5 1.13 (0.90–1.41) 0.90 (0.73–1.10) 1.06 (0.87–1.28) 1.04 (0.81–1.34) 1.23 (1.02–1.49)
Baseline clinical stage
Advanced stage 2.42 (1.83–3.21) 2.37 (1.66–3.37) 1.94 (1.59–2.37) 1.45 (1.19–1.78) 1.39 (1.17–1.65)
Region
South Africa 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Europe 0.30 (0.25–0.36) 0.41 (0.31–0.54) 0.39 (0.32–0.48) 0.37 (0.30–0.47) 0.46 (0.37–0.58)
North America 0.40 (0.31–0.50) 0.72 (0.53–0.97) 0.84 (0.66–1.07) 0.94 (0.74–1.20) 1.62 (1.27–2.05)
The above patient numbers and models are the basis for crude and adjusted mortality rate ratios as presented in Table 2 and Figure 3 and the predictions in Figure 4.
The associations in these models are presented as adjusted rate ratios with corresponding 95% CIs in parentheses.
aDeaths in South Africa represent the estimated number of deaths after correction for mortality under-ascertainment through record linkage and re-weighting. The
proportions of deaths that were documented prior to record linkage were 63%, 53%, 51%, 47%, and 43% for the successive durations on ART reflected in the table.
doi:10.1371/journal.pmed.1001718.t003
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to Europe and North America (median 35, 38, and 43 years,
respectively). The South African patients had more advanced
disease at ART initiation, evidenced by lower CD4 counts (median
102 compared to 213 and 172 cells/ml in Europe and North
America) and more advanced clinical stage. Almost half the South
African patients (13,224, 43%) started ART in 2007 or later, in
contrast to the other regions where ART was mostly started in
earlier years.
In South Africa, 26,100 patients (85.7%) had known outcomes at
analysis closure. Among the 4,367 (14.3%) patients LTF, 2,594 (57.4%)
(Table S2) could be linked to the NPR, with 956 (36.9%) having died.
A further 1,652 (5.4%) patients transferred care and were censored at
the time of transfer. By comparison, 31% (Europe) and 18% (North
America) of patients would have been similarly classified as LTF prior
to analysis closure or four years of follow-up, while transfers were not
distinguished from other losses to care in these cohorts.
The inclusion of NPR linkage data on vital status in South Africa
more than doubled estimated cumulative all-cause mortality on ART
at four years from 7.7% to 16.6% (95% CI 15.4%–17.4%). Crude
cumulative four-year mortality was 4.7% (4.4%–4.9%) in Europe and
15.3% (14.3%–16.5%) in North America (Figure 1). Mortality after
one year on ART was higher in South Africa (9.7%, 95% CI 9.2%–
10.1%) than in Europe (2.0%, 1.8%–2.2%) or North America (4.6%,
4.0%–5.1%). The higher early mortality in South Africa was especially
evident in patients with CD4 count ,50 cells/ml at start of ART
(Figure 2). For patients initiating ART with initial CD4 count between
50 and 199 cells/ml, crude cumulative all-cause mortality in North
America at four years exceeded that in South Africa. In sensitivity
analyses restricted in Europe and North America to patients with
recorded heterosexually acquired HIV, crude cumulative mortality in
North America was consistently lower than in the overall study
population in South Africa and differences with Europe were reduced
(Figures S1 and S2).
Figures 3A and 3B display crude and adjusted (for baseline
characteristics) mortality rate ratios comparing Europe and North
America with South Africa by duration on ART. Mortality rates
were lower in Europe and North America than in South Africa
during the first year of ART, lower in Europe but comparable in
North America between 12 and 24 months, and lower in Europe
and higher in North America between 24 and 48 months on ART
(adjusted rate ratios [ARRs] 0.46, 95% CI 0.37–0.58 for Europe
and 1.62, 95% CI 1.27–2.05 for North America, compared to
South Africa) (Tables 2 and 3). This pattern was little changed by
further correction for sites’ self-estimated completeness of mortal-
ity ascertainment (Figure 3C). When analyses of mortality in
Europe and North America were restricted to patients with sexual
transmission, adjusted mortality rates were lower in Europe and
North America than in South Africa for the first two years on
ART, and lower in Europe but comparable to North America
between 24 and 48 months (Figure 3D). These attenuated
differences between Europe and North America were evident in
additional sensitivity analyses with further restriction to patients in
Europe and North America with recorded heterosexually acquired
HIV (compared to the overall study population in South Africa),
Figure 1. Cumulative incidence of mortality up to four years after start of ART by region, corrected in South Africa for mortality
under-ascertainment.
doi:10.1371/journal.pmed.1001718.g001
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or those starting ART more recently (Table 2). Assuming that a
proportion of patients LTF in European and North American
cohorts had died resulted in higher mortality in both Europe and
North America than in South Africa after 1 year on ART, while
further attenuating differences between Europe and North
America, especially when mortality in patients LTF was assumed
to be lower in North America than in Europe.
Viral load measurements at 6 months on ART were available
for 55.6%, 86.7%, and 81.7% of patients in South Africa, Europe,
and North America, respectively, with 89.5%, 89.5%, and 73.4%,
respectively, achieving suppression to below 400 copies/ml.
Adjusted comparisons of mortality restricted to patients who
achieved suppression demonstrated broadly similar inter-regional
differences to the primary adjusted comparison, but with a
reduction in mortality rate ratios comparing North America to
South Africa beyond a year on ART (Table 2). Predicted mortality
by individual cohort was comparable for the South African cohorts
up to two years on ART, but varied more substantially early on
treatment between cohorts within Europe and North America
(Figure 4).
The proportion of classifiable deaths that were classified as from
unnatural causes was 2.8%, 5.1%, and 8.6% in South Africa,
Europe, and North America, respectively. In Europe 525 (47.4%)
of 1,107 coded deaths were due to AIDS compared to 128 (52.5%)
of the 244 coded deaths in North America. In both of these regions
30% of deaths were due to infection, the majority being AIDS-
defining (20%).
Standardised 1990 mortality from representative countries,
illustrative of differences in mortality prior to the effects of
HIV and hence of background mortality, was substantially
lower in Europe and North America (41% and 46% of South
Africa, respectively, 682 deaths/100,000 years in South
Africa).
Discussion
To our knowledge this is the first comparison of mortality up to
four years after starting ART between high-income countries and
a high HIV-burden setting in Southern Africa with near-complete
mortality ascertainment. The high early mortality in patients in
South Africa starting ART, which was first reported in an earlier
comparative analysis [9], occurs mainly in patients who were
severely immunosuppressed (CD4 count ,50 cells/ml) at the start
of ART. Differences in mortality rates between South Africa,
Europe, and North America are markedly reduced or even
reversed thereafter.
The ART cohort collaboration recently described substantial
differences between mortality rates among HIV cohorts in Europe
and North America [13], which arose from a combination of
health services factors, patients’ socio-economic and behavioural
characteristics, co-morbidities such as HCV, and differential
mortality ascertainment. The current analysis confirms that these
differences are largely mediated through adverse outcomes in
patients with transmission via injection drug use or with unknown
mode of transmission given the attenuation in these differences in
analyses restricted to patients with sexual transmission of HIV.
ART treatment settings are often dichotomised as resource-limited
and resource-replete, but the results reported here emphasise the
importance of considering a range of contextual issues when
comparing mortality between cohorts and settings, irrespective of
region.
Mortality Ascertainment
The manner in which LTF is incorporated into HIV cohort
analyses can substantially impact findings [28,29]. Analyses of
South African ART data are increasingly based on a repeatable
and structured method for incorporating data from the NPR
Figure 2. Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ART initiation, corrected
in South Africa for mortality under-ascertainment.
doi:10.1371/journal.pmed.1001718.g002
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[15,25,30,31], which effectively ensures that every patient LTF is
reclassified as alive or deceased. Half of the deaths in South Africa
were ascertained based on death registry linkage, and it has been
demonstrated for patients in the participating cohorts that between
90% and 95% of known deaths are identified by the registry [15].
The residual proportion of deaths not ascertained is therefore
likely to be very low.
Most European and North American cohorts assume that
patients LTF have the same outcomes as retained patients. Where
mortality ascertainment through registries is frequent and com-
prehensive, as in the North American cohorts included here, this
may over-estimate mortality because most deaths in patients LTF
will already have been ascertained. If LTF is high without the
possibility of registry linkage, as in many high burden settings
[32,33], or linkage is irregular or incomplete as in some European
cohorts, mortality may conversely be underestimated. Correction
for cohort-assessed completeness of mortality ascertainment had a
limited effect on our results, possibly due to poor accuracy of this
assessment. Assuming however that a plausible proportion of
patients LTF in Europe and North America had died substantially
reduced the differences between European and North American
cohorts, particularly when mortality in these patients was assumed
to be higher in Europe than North America in keeping with
differences in the completeness and frequency of death registry
linkage.
Future cohort analyses of mortality should be explicit as to the
frequency and completeness of death registry linkage, the manner
in which additional data from registries are incorporated into the
data or analyses, and the analytic approach to defining and
correcting for losses to care. Robust data on outcomes in patients
LTF in Europe and North America will assist future analyses.
Clinic Versus Population-Based Cohorts
Some of the South African and North American cohorts are
geographically defined population-based cohorts. Mortality differ-
ences between clinic or hospital and population-based cohorts can
be ascribed both to patient characteristics (population-based
cohorts may include more marginalised patients with higher
Figure 3. Relative mortality by region and duration on ART comparing European and North American cohorts to South Africa. (A)
Crude rates, (B) adjusted for baseline covariates*, (C) corrected for cohort-assessed mortality under-ascertainment** and adjusted
for baseline covariates, and (D) limited in Europe and North America to patients with sexual acquisition of HIV, adjusted for
baseline covariates. *Adjusted for baseline gender, CD4 count, clinical stage, viral load, and calendar period. **In order to correct for cohort-
assessed completeness of mortality ascertainment, mortality was predicted for each region and duration from a multivariable model for each cohort
for women aged 30–45 starting ART with a CD4 count 100–199 cells/ml in 2004–2007, with advanced clinical stage and viral load 4–5 log copies/ml.
Each mortality rate in Europe and North America was multiplied by the inverse of the cohort-assessed proportion of deaths ascertained (weighted
estimate from participating cohorts), prior to converting to rate ratios relative to South Africa.
doi:10.1371/journal.pmed.1001718.g003
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mortality) [13], and to biases resulting from patients moving from
or being lost to facility-based care. Paradoxically higher on-ART
mortality in a population-based cohort might reflect better
coverage of hard-to-reach patients and lower population-level
HIV-related mortality. Although in practice it may be problematic
to strictly dichotomize cohorts as being clinic or population-based;
potential differences in mortality ascertainment arising from
service models requires consideration in on-ART mortality
analyses.
Access to and Quality of Health Care
High early mortality in South Africa relative to the other
settings occurs mainly in patients with severe immunosuppression
at ART initiation. Poor access to care is an important contributor
to late presentation, whether due to disease burden outstripping
public sector resources as in South Africa, or due to marginalised
communities having limited access to health care in better
resourced settings [34,35].
There are likely pathogen- and disease-burden related contri-
butions to higher early mortality on ART in South Africa, which
are exacerbated in the context of delayed access to care, including
undiagnosed tuberculosis, cryptococcal disease, and severe bacte-
rial infections [12,36–38]. Detailed data on causes of death were
not available from the South African cohorts; however, published
studies of both inpatient and outpatient ART mortality in South
Africa suggest that the majority of deaths were due to AIDS-
defining or HIV-associated associated infections, especially tuber-
culosis, which is frequently undiagnosed at the time of death
[39,40]. This finding contrasts with the 30% of classifiable deaths
in Europe and North America that were infection-related.
It is also possible that measures used to adjust analyses for
disease severity reflecting delayed access to care, such as CD4
count and clinical stage, may not fully capture differences in
severity, resulting in residual confounding in comparative analyses.
In patients with advanced disease, background differences in
health outcomes between regions, as reflected by differences in the
pre-HIV-era mortality, may be accentuated in the early period on
ART. By contrast it is possible that once well-established on ART,
patients who have managed to access and remain part of a
dedicated care program are advantaged relative to other public
sector patients, narrowing differences that might be predicted
based on comparisons of background mortality. This phenomenon
has been described with respect to men and women in South
Africa, where differentials in on-ART mortality are lower than for
similarly aged citizens without HIV [30].
HIV Disease Progression and Response to Treatment
Higher mortality in North America than South Africa after 2
years on ART appeared partially attributable to a lower
proportion of patients achieving virologic suppression in North
Figure 4. Predicted mortality by cohort and region. Predicted for women aged 30–45, starting ART with a CD4 count 100–199 cells/ml in 2004–
2007, advanced clinical stage, and viral load 4–5 log copies/ml. The squares are scaled to the square root of cohort size, the horizontal lines represent
95% CIs, and the dotted vertical lines represent regional estimates for each duration. A mortality rate could not be estimated for one European cohort
between 6 and 12 months on ART due to the absence of events. RSA, South Africa; NA, North America; EUR, Europe.
doi:10.1371/journal.pmed.1001718.g004
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America, compared with South Africa and Europe. This finding is
consistent with lower adherence to therapy in marginalised groups
in some North American settings [41].
Although comparative data on disease progression were not
available from South Africa, previous analyses comparing
European and North American cohorts within the ART Cohort
Collaboration demonstrated that inter-cohort differences in
progression to AIDS are attenuated by the same factors that
attenuate differences in mortality [13]. Interestingly, the ordering
of cohorts by progression to AIDS differed from the ordering for
mortality, which supports inter-cohort and inter-regional differ-
ences in mortality arising both from differences in the clinical
progression of HIV and for other reasons.
Patient Factors Independent of HIV Disease
Patients differ markedly between contexts, and this is crudely
explored in our study by mode of HIV transmission. In some
cohorts, particularly in the USA and Canada, many patients with
HIV are from marginalised groups with high background
mortality and prevalence of co-morbidities such as HCV. The
importance of non-HIV mortality risk factors was demonstrated in
the Danish HIV Cohort Study, where mothers of HIV-infected
individuals were shown to have higher rates of myocardial
infarction than population-matched controls [42], and non-HIV
risk factors (co-morbidities including HCV and alcohol and drug
abuse) explained a considerable component of differential
mortality on treatment [43]. Co-morbidity may contribute to
later mortality on ART in context-specific ways: for example HCV
infection may impact later mortality in the North America cohorts
in this study, in which a high proportion of patients are or were
previously injecting drug users [44]. In South Africa where HIV
affects the general population, those accessing care may have been
exceptionally motivated citizens, especially in the early years of the
programs when treatment availability was more limited.
Strengths and Limitations
The analytical approach based on death registry linkage
minimises bias resulting from under-ascertainment of mortality.
The manner of incorporation of registry data differed, however,
between the regions and could have still biased results, most
importantly the less frequent linkages to mortality registries in
Europe. The approach to accounting for patient transfers was also
not standardized across regions. In the South African cohorts data
on mode of HIV transmission, progression to AIDS, and cause of
death were not available, and baseline data on viral load and
clinical stage were available in less than half the patients, limiting
the range and precision of comparative analyses. The four-year
duration of follow-up is a further strength of the paper, but, given
the continued rapid scaling up of ART and evolution of treatment
guidelines, patterns of relative mortality may have evolved
subsequent to the closure of this analysis. It was not possible
however to use more recent data from South Africa, as following
the initial linkage exercises, three of the included cohorts began
incorporating the NPR mortality data into their primary data
systems, invalidating the subsequent use of the up-weighting
procedures described in this paper.
Conclusions
With increasing duration on ART, mortality in HIV-infected
patients on treatment in South Africa declines rapidly to levels
approaching those in high-income settings. Contextual factors
related to measurement, health services, and patient characteristics
account for a large proportion of regional mortality variation and
are key to interpreting mortality on ART both within and between
settings. Such comparisons remain an invaluable tool for exploring
treatment responses to the HIV pandemic and developing health
systems that best serve patients in these different settings.
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Editors’ Summary
Background. AIDS has killed about 36 million people since
the first recorded case of the disease in 1981, and a similar
number of people (including 25 million living in sub-Saharan
Africa) are currently infected with HIV, the virus that causes
AIDS. HIV destroys immune system cells (including CD4 cells,
a type of lymphocyte), leaving infected individuals suscep-
tible to other serious infections. Early in the AIDS epidemic,
HIV-positive people usually died within 10 years of becoming
infected. In 1996, effective antiretroviral therapy (ART)
became available and, for people living in high-income
countries, HIV infection became a chronic condition. But ART
was expensive, so HIV/AIDS remained largely untreated and
fatal in resource-limited countries. Then, in 2003, the
international community began to work towards achieving
universal access to ART. By the end of 2012, nearly two-thirds
of HIV-positive people (nearly 10 million individuals) living in
low- and middle-income countries who were eligible for
treatment because their CD4 cell count had fallen below
350/mm3 blood or because they had developed an AIDS-
defining condition were receiving treatment.
Why Was This Study Done? It is known that a larger
proportion of HIV-positive patients starting ART die during
the first year of treatment in sub-Saharan Africa than in
Europe and North America. This difference arises in part
because patients in resource-limited settings tend to have
lower CD4 counts when they start treatment than patients in
wealthy countries. However, the lack of reliable data on
mortality (death) in resource-limited settings has made it
hard to compare longer-term outcomes in different settings.
Information on the long-term outcomes of HIV-positive
patients receiving ART in resource-limited countries is
needed to guide the development of appropriate health
systems and treatment regimens in these settings. In this
collaborative analysis of prospective cohort studies, the
researchers compare mortality up to 4 years on ART in South
Africa, Europe, and North America. A prospective cohort
study follows a group of individuals over time to see whether
differences in specific characteristics at the start of the study
affect subsequent outcomes. A collaborative analysis com-
bines individual patient data from several studies.
What Did the Researchers Do and Find? The researchers
combined data from four South Africa cohorts of HIV-
positive patients starting ART included in the International
Epidemiologic Databases to Evaluate AIDS South African
(IeDEA-SA) collaboration with data from six North American
cohorts and nine European cohorts included in the ART
Cohort Collaboration (ART-CC). The South African cohorts
were chosen because unusually for studies undertaken in
countries in sub-Saharan Africa the vital status of patients
(whether they had died) who had been lost to follow-up in
these cohorts could be obtained from the national
population register. Patients in South Africa began treat-
ment with more advanced disease (indicated by a lower
average CD4 count) than patients in Europe or North
America. Notably, high early mortality after starting ART in
South Africa occurred mainly in patients starting ART with a
CD4 count below 50 cells/mm3. The cumulative mortality
after 4 years of ART was 16.6%, 4.7%, and 15.3% in South
Africa, Europe, and North America, respectively. After
adjusting for patient characteristics at ART initiation, the
mortality rate among patients beginning ART was initially
lower in Europe and North American than in South Africa.
However, although the adjusted mortality rate in Europe
remained lower than the rate in South Africa, the rate in
North America was higher than that in South Africa
between 24 and 48 months on ART.
What Do These Findings Mean? Although the linkage to
national vital registration systems (databases of births and
deaths) undertaken in this collaborative analysis is likely to
have greatly reduced bias due to under-ascertainment of
mortality, the accuracy of these findings may still be limited
by differences in how this linkage was undertaken in
different settings. Nevertheless, these findings suggest that
mortality among HIV-infected patients receiving ART in
South Africa, although initially higher than in Europe and
North America, rapidly declines with increasing duration on
ART and, after 4 years of treatment, approaches the rate
seen in high-income settings. Intriguingly, these findings
also highlight the relatively higher late mortality in North
America compared to either Europe or South Africa, a result
that needs to be investigated to explore the extent to which
differences in mortality ascertainment, patient characteris-
tics and comorbidities, or health systems and treatment
regimens contribute to variations in outcomes among HIV-
positive patients in various settings.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001718.
N This study is further discussed in a PLOS Medicine
Perspective by Agnes Binagwaho and colleagues
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on universal access to ART, on HIV and AIDS in sub-
Saharan Africa, and on HIV and AIDS in South Africa (in
English and Spanish)
N The World Health Organization provides information on all
aspects of HIV/AIDS (in several languages); its 2013
Consolidated guidelines on the use of antiretroviral drugs
fo r t rea t ing and prevent ing HIV in fec t ions :
recommendations for a public health approach are
available
N The 2013 UNAIDS World AIDS Day Report provides up-to-
date information about the AIDS epidemic and efforts to
halt it
N Information about the International Epidemiologic
Databases to Evaluate AIDS South African (IeDEA-SA)
collaboration and about the ART Cohort Collaboration is
available
N Personal stories about living with HIV/AIDS are available
through Avert, Nam/aidsmap, and Healthtalkonline
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